Dalfampridine in hereditary spastic paraplegia: a prospective, open study.
Fiche publication
Date publication
mai 2015
Journal
Journal of neurology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Béreau M, Anheim M, Chanson JB, Tio G, Echaniz-Laguna A, Depienne C, Collongues N, de Sèze J
Lien Pubmed
Résumé
Our aim was to support the use of dalfampridine as a treatment for patients affected with hereditary spastic paraplegia (HSP). We performed a prospective, uncontrolled, proof of concept, open trial. We included 12 HSP patients defining the total group (TG) who received dalfampridine 10 mg twice daily for 2 weeks. Efficacy assessment was based on walking ability improvement. The Timed-25-Foot Walk Test, the Spastic Paraplegia Rating Scale (SPRS), and the 12-item Multiple Sclerosis Walking Scale (MSWS-12) were performed before and after treatment. Safety assessment was based on adverse events occurrence. A significant improvement in SPRS (p = 0.0195) and MSWS-12 (p = 0.0429) was noted after treatment in the TG. No serious adverse events were noted. This interventional study provides encouraging results supporting the use of dalfampridine in HSP.
Mots clés
4-Aminopyridine, therapeutic use, Adult, Aged, Alkaloids, Analysis of Variance, Female, Follow-Up Studies, Humans, Male, Middle Aged, Potassium Channel Blockers, therapeutic use, Prospective Studies, Severity of Illness Index, Spastic Paraplegia, Hereditary, drug therapy, Walking, physiology
Référence
J. Neurol.. 2015 May;262(5):1285-8